This conversation focuses on why it will be challenging to use currently-available NITs to stage patients with advanced MASH fibrosis (F2/F3) accurately with current test options.
This conversation focuses on why use of NITs is such a pivotal issue for MASH treatment and drug adoption, particularly if, as expected, the first MASH drug is approved this month.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
This conversation reviews several other topics related to the new MASLD nomenclature: impact on NITs and ICD codes, future vision for MASH, and general satisfaction with the process to date.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.
In this March, 2023 conversation, Jeff McIntyre from Global Liver Institute talks with Louise Campbell and Roger Green about key upcomoing regulatory events, including an ICER review of resmetirom and obeticholic acid and an FDA workshop on NITs.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to describe their priority MASH programs for 2024.
Hepatology researcher, key opinion leader and 2023 UEG Rising Star of the Year Hannes Hagstrom joins Louise Campbell and Roger Green in a far-ranging discussion focusing largely on issues in diagnostics and clinical care pathways.
Hepatology researcher and Key Opinion Leader Naim Alkhouri joins Louise Campbell and Roger Green to discuss advances in drug development and NITs and to share thoughts about efficacious use of clinical care pathways.
Patient advocates Mike Betel and Tony Villiotti join Jörn Schattenberg and Roger Green to discuss key events in MASLD 2023 from a patient point of view.
